Germany's biotech industry is thriving. Revenues more than tripled in 2021 compared to the previous record year 2020. The biotech sector workforce increased to 44,500 (2020: 38.500) over the same period. Funding reached EUR 2.4 billion – showing that the record figures of 2020 were not a one-off exception but part of a longer trend.

A major success factor continues to be the close cooperation between biotech companies, research institutes, technology parks, and their local communities – all effectively coordinated by Germany's biotech cluster organizations. In 2021, the number of biotechnology companies in Germany increased to over 774. Biotechnology companies generated a record EUR 26.3 billion in revenue while spending EUR 3.8 billion on research and development activities.

Germany's excellent R&D environment and increased public interest in innovative therapies during the Covid-19 pandemic contributed to the exceptional revenue growth. Every year companies participate in thousands of research projects with partners from industry and research institutes – the resulting scientific output supports Germany's reputation as one of the best ecosystems for biotechnology R&D worldwide.

The "BioRegions" are cluster initiatives for the advancement of modern biotechnology in Germany – ranging from local infrastructure including technology parks to statewide organizations. Over the past three decades, these clusters have become some of the world's leading R&D hubs. Each region is run by a dedicated cluster management and facilitates collaboration between universities, R&D institutes and companies.

Around 30 BioRegions are active members of AK Bioregio "Council of German BioRegions," whose goal is to advance the German biotechnology sector by coordinating and promoting local activities. AK BioRegio advances the exchange between regional initiatives and relays its expertise to political decision-makers

# Germany's Biotechnology Industry in Numbers

### EUR 26.3 bn revenue

+279 percent compared to 2019

## **44,500** *employees*

+16 percent compared to pre-Corona period

# EUR 3.8 bn R&D spending


+54 percent increase

# 774 companies

including 24 listed corporations

#### **Biotech Companies in Germany**

in EUR billion




Source: BMWK; Ernst & Young Biotechnologie-Report Deutschland 2021 BIO Deutschland

# Biotechnology Clusters in Germany

Biotechnology clusters in Germany include local technology parks and accelerators as well as organizations that operate on a regional or state level. Dedicated cluster managements provide a range of services, such as obtaining funding for joint R&D projects, matching

partners, and providing educational training programs. The map illustrates the location of the clusters. The numbers refer to the corresponding numbers in the table on the right.



<b>Biotechnology Clusters</b>																															
by Research Area		arch	o.		ence									ions	es				ine			S.	g,		eering				ogy		nics
Germany's biotechnology clusters span the entire value chain. This table helps to find the right partner in Germany: Find your area of interest to identify clusters that consider this field their focus of expertise.	MEDICAL	Fundamental Research	Molecular Medicine	Cellular Biology	Pharmaceutical Science	Protein Technology	Stem Cells	Bioinformatics	Drug Discovery/ Development	Oncology	Infectious Diseases	CNS/Neurology	Immunology	Age-related Conditions	Respiratory Diseases	Novel Therapy Approaches	Gene Therapy	Cell Therapy	Personalized Medicine	Biomaterials	Synthetic Biology	Medical Technology	Diagnostics/Imaging	Lab and Analytics	(Bio)Medical Engineering	Surgery	Digital Health	Multi-application	Micro/Nanotechnology	Materials Science	Electronics/Photonics
1 BIO.NRW	•		•						•							•								•							
2 BioCon Valley	•															•			•	•		•		•	•		•				
3 BioLAGO			•							•	•								•				•	•			•				
4 BioM			•					•	•							•						•					•				•
5 BioPark Regensburg			•	•				•										•			•		•				•				
6 BMD Life Sciences	•				•	•					•								•												
7 BIOPRO																			•			•	•		•			•			
8 BioValley			•							•								•	•						•				•		
9 BioRegio STERN			•							•									•				•	•	•		•				
10 biosaxony			•							•								•							•						
11 CI3		•						•	•							•						•									
12 HealthCapital			•							•		•						•	•												
13 Life Science Nord			•					•		•	•		•						•					•							
14 medways			•											•					•							•					
15 BioRegioN			•								•	•			•			•							•						
16 Cluster Biotechnology Bavaria			•						•							•						•									
17 House of Pharma & Healthcare			•		•														•				•	•			•				
18 InfectoGnostics			•					•			•				•									•							•
19 glyconetBB			•			•				•										•			•	•						•	
20 PROXYDRUGS		•			•				•	•	•	•				•															
21 Forum MedTech Pharma	•																					•	•		•		•	•			•
22 DiagnostikNet-BB			•					•																•			•		•	•	
23 BioRN Network	•	•							•	•			•			•							•								
24 BioPharmaCluster South Germany			•			•	•			•							•	•													

Source: GTAI Cluster Survey 2022

# **Biotechnology Clusters by Field of Activity**

	Science & Technology Park	Start-up Incubator	Corporate Membership Base	Events and Networking	Research Institutes	Focus Area
1 BIO.NRW		•	•	•		
2 BioCon Valley			•	•		Health services/healthy aging, digital health
3 BioLAGO				•	•	Diagnostics, pharma, MedTech, eHealth
4 BioM		•			•	Personalzed and digital health innovation
5 BioPark Regensburg	•			•	•	
6 BMD Life Sciences	•		•		•	
7 BIOPRO		•	•	•		
8 BioValley	•			•	•	
9 BioRegio STERN	•			•	•	
10 biosaxony		•		•	•	
11 CI3					•	
12 HealthCapital		•	•		•	
13 Life Science Nord		•			•	Hygiene, infection & health, digitalization & precision medicine
14 medways		•		•	•	
15 BioRegioN		•		•	•	
Cluster Biotechnology Bavaria		•			•	Personalized and digital health
House of Pharma & Healthcare			•		•	Pharma and healthcare education, dialogue and research
18 InfectoGnostics	•		•			Infectious diseases diagnostics and research
19 glyconetBB	•		•		•	
20 PROXYDRUGS			•		•	Targeted protein degradation
21 Forum MedTech Pharma	•		•	•		
22 DiagnostikNet-BB			•	•		IVD and laboratory medicine
23 BioRN Network			•	•	•	
BioPharmaCluster South Germany	•		•			Virus-based therapeutics

# **Our Support for Your Business in Germany**

Germany Trade & Invest (GTAI) is the foreign trade and inward investment agency of the Federal Republic of Germany. We advise and support foreign companies planning to expand into the German market and assist German companies seeking to enter global markets.

**Investor Consulting** 

Our Investor Consulting division of specialist industry teams provide international investors in all sectors with comprehensive consultancy services specific to each individual investment project. Services include:

- · Market and industry reports
- · Market entry analysis
- · Business and tax law information

· Funding and financing information

All investment-related services are provided entirely free of charge and all enquiries are treated with the utmost confidentiality.



**Contact Dr. Gregor Kemper** Biotechnology Germany Trade & Invest gregor.kemper@gtai.com



## **Stay informed about Germany**



Visit us online at www.gtai.com



Follow the latest investment news on Twitter @gtai\_com



Sign up for our free Markets Germany magazine www.gtai.com/markets-germany-subscribe



Find out more about German industry at our YouTube channel www.youtube.com/user/gtai

### **Imprint**

Publisher: Germany Trade and Invest Gesellschaft für Außenwirtschaft und Standortmarketing mbH Friedrichstraße 60, 10117 Berlin, Germany T +49 30 200 099 0, invest@gtai.com

Executive Board: Dr. Jürgen Friedrich, Chairman/CEO, Dr. Robert Hermann, CEO

Editor: William MacDougall, GTAI Layout: Danielle Röbbenack, GTAI

Print: Kern GmbH, 66450 Bexbach, www.kerndruck.de

Picture Credits: Cover: @GettyImges/Andrew Brookes; back:  ${\tt @GettyImges/typhoonski; portrait: @GTAI/Illing \& Vossbeck}\\$ Fotografie

Notes: All rights reserved ©Germany Trade & Invest, August 2022

Reproduction, in whole or in part, only permissible with express prior authorization. All market data provided is based on the most current market information available at the time of publication. Germany Trade & Invest accepts no liability for the actuality, accuracy, or completeness of the information provided.

Order Number: 20829/2

Supported by:



on the basis of a decision by the German Bundestag